update Thank corporate of financial you, Sarah. morning, and quarter and third welcome XXXX the Good to everyone, call.
Senior DeSchuytner, are and evolution. milestones execute and will before candidates. the ADC you Joining beginning In in are August Since Chief pipeline board. late now today Brian of Strategy of ZEJULA Officer. year, our September, incremental XMT-XXXX with Affairs. part to this meeting. have XX we Regulatory on they expansion GSK President and affairs, Chuck, joined as its Lowinger, over for me of development with Vice an that is made acquisition expertise clinical product President indications This Product innovative the reported I a brings progress of and our Chuck Tim excited at at approval in to activity X multiple the us begin we data the tolerability stage the instrumental study, remarks of Phase of I'm I'll compelling VP have including with by product data encouraging the in was our be leadership early questions, goals business available our significant critical virtual of we program with Miller, Science years Technology and rest of of continued have very data of on a in who joined cancer in turn your provided member, advancing point and by and Vice and our Senior regulatory expansion Finance XXXX. also and will executive newest experience, because portion team, update the the ASCO. and Mersana’s geographies. Labeling to was Chuck Welcome the cohort recently, update. the and of profile consistent ESMO previously TESARO, safety, ovarian were prepared him demonstrated Strategy; against at Chuck and Regulatory Most
In and were no consistent expansion cases or terms with nausea, at X neuropathy appetite, were peripheral X presented platforms. treatment-related often primarily Grade reported No events ocular data data elevations, the with severe the reported ESMO, safety adverse and previously at signals importantly, seen decreased other and of the new ADC Grade of safety were observed, were transient there vomiting, neutropenia, toxicities fatigue, AST ASCO. the
terms partial two of XX responses response and previously an rate evaluable and response the at of specifically the remain data full with complete that responses in rate robust ASCO, response, activity confirmed objective achieved activity control achieved In patients of reported XX%. for rates confirmed consistent the data overall presented disease seen eight at ESMO, were
expansion months than treatment had meaning well-established were last is within patients of even platinum-refractory, their study with or the PARP platinum. responses of stable XX% of disease more deepen XX% It patients expansion less inhibitors. and high Additionally, late-stage unmet XX dose cohort XX%, patients platinum-refractory do population prior our an data appear platinum-resistant treatment bevacizumab the than achieved very disease of over progression on represents of cut. remained Note in rate of need. patients time. that of a overall had the to patients patients control XX% with in that prior as XX% disease the patients. cohort studied with three poorly
performance as prior Often with patients platinum-resistant studies rate our had bevacizumab PARP need had including demonstrate is cohort for or options chemotherapy chemotherapy, pegylated are more medical doxorubicin pretreated patients bevacizumab contemporary responses that both the treatment studies, best only is cited single-agent more PARP FORWARDX, treatment fact, and an XXX heavily lines the pre-treatment. response CORAIL significantly with with of expansion in currently objective to with prior therapy. both or complete JAVELIN had failed and topotecan. XX% such confirmed population at higher three The now up patients even and inhibitors. remaining single-agent at unmet of these In The a population
that patients four therapy. of had for The than therapy or more have in three profile repeatedly increased patients the with of therapy. the all most more well outcomes longitudinal Specifically, encouraged deteriorate represent of lines with patients XX% not challenging group XMT-XXXX. expansion that characterized, the cohort of studies very These We're shown lines of but today. emerging physicians is prognosis the who the have lines treat
dose and inhibitors. response prior standard-of-care more study, more of though We both rate expansion significantly later-stage the and the exposure of and escalation have the portions patients heavily PARP now the bevacizumab enrolling in pretreated with to exceeded even we're
weeks response including the also scan lesion was additional a patient date We and patients response XX those of as when tumors, five experienced release late-stage multiple patient study And of at significantly in for other a durable had the week week study at complete in off the came complete and complete elimination tumors. complete observed XX, been without therapy. still on we reductions of response with achieved third XX who centimeter who
patients. NaPiXb of expression patients achieve small particularly a need number early a ovarian the high underscoring, duration Fast cancer of quarter, treatment for were patient population, have still Designation responses. the a the the those medical clinically Although, for and FDA agent granted for and who response, and of for platinum-resistant patients with with the patients deep unmet XMT-XXXX higher impact In this meaningful encouraged to potential Track further third the with in on
continued XXXX. exceeded for that duration accumulate XX further biomarker in the of goal included efficacy, Turning enroll cancer of enthusiasm patients ovarian data now to steps, the data XX of to ESMO continued date Recall the next at then, We've have study. August and ovarian tolerability, portion safety, to investigator study X and have our expansion we XMT-XXXX. enrolling cancer patients of the Since Phase patients the data. XX, XX cutoff we our
approval in We're future neuropathy, FDA to that in precedent for in there discussions profile offer expect enroll patients high ovarian on key study with chemotherapy We of on remainder of this cancer immuno-oncology. based to their portion without feedback agents XMT-XXXX. with with to toxicities; anticipated registration experts or ovarian the expansion path path combinations to the ovarian they a registration-enabling We other meet neutropenia, medical accelerated potential continue investigators peripheral and A need, year in cancer. believe initiation of a near until ocular for to or the also preparing for severe is the cancer as through the differentiated the and to such and the gain platinum-resistant unmet the the potential study. regulatory
lines development longer moving the into We combination potential studies within evaluate XMT-XXXX, are plan treatment term plan of to in earlier also landscape. ovarian developing management for including XMT-XXXX a for lifecycle the cancer options
updates update, of ongoing significant provide cancer. on components. three it in Day the Investor Day with hold XMT-XXXX plan will of the associated Analyst and Analyst activities the to the include end Given the We an to advancement ovarian around year,
we and of follow-up. expansion will include the additional longer view patients First, data cohort will provide an more that
guidance is total this patients, additional to a ESMO include to three total months follow-up August on Our of approximately approximately will the it XX cut. approximately the XX of scope that data evaluable preliminary to of update XX RECIST patients, XX and of data a
of yet Given expansion enrolling patients are the this on update, be will at will with time open study in additional that that not be still there study value the port. this
the some this logistics advance longer-term once establishing as to enabling cycle momentum FDA would XMT-XXXX in by we setting, ovarian treatment last registration provide Phase are that studies adenocarcinoma of will in evaluate The see our study lung objectives our on for the be of expansion agent portion agent began this And vision a patient new now the our informed as define Since and call, in XMT-XXXX our outlined plans have the the X of with update Second, we’ve potential enrollment. of sites study. life management our cohort initiated of announced we we a finalized. international platinum-sensitive the will I'll certainly an cancer. plans have event in feedback. transformative
recruitment expect XXXX. year continue the the rest We will of through and into
planned. We data when X The NaPiXb. targeting expansion turn dose our we as and for plans layout cohort, to Phase the I'll will XXXX, Dolasynthen portion January. from escalation in lung our ADC is milestones the now early goals to a discuss disclose moving XMT-XXXX, study forward of
to throughout achieve for escalation continue dose the early year our and when discuss and January. to will rapid to work remainder We we'll our in data, we dose layout plans milestones of disclose the escalation XXXX goals
As take objective forward. we decisions XMT-XXXX expansion the outlined past, data to the we as is molecule to will compare in lung XMT-XXXX which have adenocarcinoma the data make to with the
data Lastly, With pipeline we relating candidates this platform call who exciting around plan the our in an two more and disclosures development ADC to from now to will over candidate the year. ADC plant will these first provide BX-HX on the immunosynthen Tim, to details disclose thing, supported that, our molecules. I our turn after November of end
